Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,536.20GBp
22 Feb 2019
Change (% chg)

-1.80 (-0.12%)
Prev Close
1,538.00
Open
1,522.00
Day's High
1,538.60
Day's Low
1,515.20
Volume
7,440,254
Avg. Vol
8,732,481
52-wk High
1,648.80
52-wk Low
1,269.80

Latest Key Developments (Source: Significant Developments)

GSK Continues To Expect HIV Portfolio To Be 'Meaningful' Growth Driver
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - GlaxoSmithKline PLC ::GSK SAYS CONTINUES TO EXPECT HIV PORTFOLIO WILL BE A MEANINGFUL GROWTH DRIVER, INCLUDING IN 2019 - CONF CALL.GSK SAYS WITH GENERIC ADVAIR, EXPECT PARTICULAR VOLATILITY ACROSS Q1, Q2 AS MARKET ADJUSTS INVENTORY IN RESPONSE TO SUPPLY AVAILABLE - CONF CALL.GSK - EXPECT PHARMACEUTICAL BUSINESS OVERALL TO SEE A SLIGHT SALES DECLINE IN 2019 BEFORE RETURNING TO GROWTH IN 2020.GSK SAYS FROM Q1 2019, WILL REPORT OLDER RESPIRATORY PRODUCTS, INCLUDING ADVAIR SERETIDE WITHIN ESTABLISHED PHARMACEUTICALS.GSK SAYS FY CONSUMER SALES GREW 2 PERCENT DESPITE DRAG OF ABOUT 1 PERCENT POINT FROM IMPACT OF DIVESTMENT OF NONSTRATEGIC BRANDS, Q4'S IMPACT TO GST IN INDIA.GSK SAYS 2019 CASH FLOWS WILL SEE A "STEP DOWN" AS ADVAIR GENERIC FLOWS THROUGH AND CO PAYS OUT DEBT PAYMENTS ON PRE GENERIC SALES OF ADVAIR.GSK SAYS "REMAIN COMFORTABLE THAT THE BALANCE SHEET CAN SUPPORT OUR FUTURE INVESTMENT REQUIREMENTS".  Full Article

GlaxoSmithKline Posts Qtrly Adjusted EPS 31.2 Pence
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - GlaxoSmithKline PLC ::FINAL RESULTS.FY ADJUSTED EPS ROSE 7 PERCENT TO 119.4 PENCE.EXPECT FY 2019 ADJUSTED EPS TO DECLINE -5 PCT TO -9 PCT CER REFLECTING RECENT APPROVAL OF A GENERIC COMPETITOR TO ADVAIR IN US.EXPECT 80P DIVIDEND FOR 2019.QTRLY TURNOVER 8,197 MILLION STG VERSUS 7,639 MILLION STG REPORTED A YEAR EARLIER.QTRLY TOTAL EPS 24.7 PENCE.FY GUIDANCE REFLECTS EXPECTED IMPACT OF TESARO DEAL, ASSUMES CONSUMER HEALTHCARE NUTRITION DISPOSAL & CONSUMER JV WITH PFIZER CLOSE.FY SHINGRIX SALES 784 MILLION POUNDS, +>100 PCT AER, +>100 PCT CER.QTRLY PHARMACEUTICALS TURNOVER 4,810 MILLION POUNDS VERSUS 4,540 MILLION POUNDS REPORTED A YEAR EARLIER.FOCUSED ON COMPLETING TRANSACTIONS TO DIVEST CONSUMER HEALTHCARE NUTRITION BUSINESS TO UNILEVER.23 PENCE DIVIDEND DECLARED FOR QUARTER; 80P FOR FULL YEAR 2018.QTRLY VACCINES TURNOVER 1,479 MILLION POUNDS VERSUS 1,208 MILLION POUNDS REPORTED A YEAR EARLIER.QTRLY CONSUMER HEALTHCARE TURNOVER 1,908 MILLION POUNDS VERSUS 1,891 MILLION POUNDS REPORTED A YEAR EARLIER."WE ARE MAKING GOOD PROGRESS AGAINST OUR PRIORITY TO REBUILD OUR PHARMACEUTICALS PIPELINE, PARTICULARLY IN ONCOLOGY".IF EXCHANGE RATES HOLD AT 31 JAN RATES FOR REST OF 2019, ESTIMATED POSITIVE IMPACT ON 2019 STERLING TURNOVER GROWTH TO BE LESS THAN 1 PCT.IF EXCHANGE GAINS/LOSSES WERE RECOGNISED AT SAME LEVEL AS 2018, ESTIMATED POSITIVE IMPACT ON 2019 STERLING ADJUSTED EPS GROWTH WOULD BE AROUND 1 PCT.  Full Article

GSK And Merck Announce Global Alliance For M7824
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - GlaxoSmithKline PLC ::GSK AND MERCK ANNOUNCE GLOBAL ALLIANCE FOR M7824.MERCK KGAA, DARMSTADT, GERMANY WILL RECEIVE AN UPFRONT PAYMENT OF EUR 300 MILLION (£260 MILLION).PROPOSED DEAL FOR TOTAL POTENTIAL DEAL VALUE OF UP TO EUR 3.7 BILLION (£3.2 BILLION).EIGHT HIGH PRIORITY IMMUNO-ONCOLOGY CLINICAL DEVELOPMENT STUDIES ONGOING OR EXPECTED TO COMMENCE IN 2019.  Full Article

Mylan Announces FDA Approval Of Wixela Inhub, The First Generic Of ADVAIR DISKUS
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Mylan NV ::MYLAN ANNOUNCES FDA APPROVAL OF WIXELA™ INHUB™ (FLUTICASONE PROPIONATE AND SALMETEROL INHALATION POWDER, USP), FIRST GENERIC OF ADVAIR DISKUS® (FLUTICASONE PROPIONATE AND SALMETEROL INHALATION POWDER).MYLAN NV - WIXELA INHUB, THE FIRST GENERIC OF ADVAIR DISKUS, WILL LAUNCH IN H2 OF FEBRUARY.  Full Article

Exagen Extended Agreement With GSK
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - EXAGEN::EXAGEN - EXTENDED ITS AGREEMENT WITH GSK.EXAGEN - DETAILS OF AGREEMENT ARE CONFIDENTIAL.  Full Article

Epizyme Earns $8 Mln Milestone Payment From Glaxosmithkline For Initiation Of Clinical Development For First-In-Class Prmt1 Inhibitor
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Epizyme Inc ::EPIZYME EARNS $8 MILLION MILESTONE PAYMENT FROM GLAXOSMITHKLINE FOR INITIATION OF CLINICAL DEVELOPMENT FOR FIRST-IN-CLASS PRMT1 INHIBITOR.EPIZYME INC - CO GRANTED GSK EXCLUSIVE WORLDWIDE LICENSE RIGHTS TO METHYLTRANSFERASE INHIBITORS DIRECTED TO 3 TARGETS.EPIZYME INC - EARNED AGGREGATE OF $89 MILLION IN UP-FRONT, RESEARCH & MILESTONE PAYMENTS TO DATE.EPIZYME INC - MAY RECEIVE UPTO ADDITIONAL $375 MILLION FROM GSK IF ALL REMAINING MILESTONES ARE MET.EPIZYME INC - ELIGIBLE TO RECEIVE UP TO DOUBLE-DIGIT ROYALTIES ON WORLDWIDE NET SALES OF COLLABORATION PRODUCTS.  Full Article

GSK Commences Tender Offer For Tesaro Inc
Friday, 14 Dec 2018 

Dec 14 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - GSK COMMENCES TENDER OFFER FOR TESARO INC.GLAXOSMITHKLINE PLC - COMMENCING CASH TENDER OFFER FOR ALL OF ISSUED, OUTSTANDING SHARES OF COMMON STOCK OF TESARO FOR PRICE OF $75.00 PER SHARE.GLAXOSMITHKLINE - TENDER OFFER COMMENCED ON DECEMBER 14, 2018 AND WILL EXPIRE ON JANUARY 14, 2019.  Full Article

Vectura Says Considering Options Regarding GSK Patent Litigation
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Vectura Group PLC ::UPDATE ON UK GSK PATENT LITIGATION.WILL BE CONSIDERING OUR OPTIONS REGARDING COURT DECISION, WHICH COULD INCLUDE SEEKING PERMISSION TO APPEAL.JUDGEMENT IN ACTION BY GSK AGAINST CO IN RELATION TO SOME MORE PATENTS UNDER PATENT LICENCE AND OPTION AGREEMENT WITH VECTURA.COURT'S "OVERALL RULING IN FAVOUR OF GSK" FOR THE LITIGATION.  Full Article

Neurometrix Reports Agreement With GSK Healthcare On 2019 Quell Development Program
Tuesday, 11 Dec 2018 

Dec 11 (Reuters) - NeuroMetrix Inc ::NEUROMETRIX REPORTS AGREEMENT WITH GSK HEALTHCARE ON 2019 QUELL JOINT DEVELOPMENT PROGRAM AND MODIFICATION TO STRATEGIC COLLABORATION.PARTIES MODIFIED TERMS OF COLLABORATION TO REALLOCATE UP TO $13.8 MILLION REMAINING TO BE PAID BY GSK.REPORTED AGREEMENT REACHED ON 2019 DEVELOPMENT PROGRAM AND IT WILL COMMENCE IN JANUARY 2019.MODIFICATIONS ACCELERATED PORTION OF REMAINING MILESTONES TIMING INTO NEXT 12 MONTHS.NEUROMETRIX RECEIVED A $2 MILLION MILESTONE PAYMENT FROM GSK IN CONNECTION WITH MODIFICATIONS.MODIFICATIONS REDUCED AGGREGATE MILESTONE AMOUNT PAYABLE BY AN INTEREST CHARGE.  Full Article

Crown Laboratories Acquires Select Consumer Healthcare Brands From Glaxosmithkline
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Crown Laboratories ::CROWN LABORATORIES ACQUIRES SELECT CONSUMER HEALTHCARE BRANDS FROM GLAXOSMITHKLINE.FINANCIAL TERMS OF TRANSACTION WERE NOT DISCLOSED.HAS ACQUIRED NORTH AMERICAN DISTRIBUTION RIGHTS OF 5 OTC CONSUMER BRANDS FROM GLAXOSMITHKLINE.SAYS HAYFIN CAPITAL MANAGEMENT, LLP PROVIDED DEBT FINANCING IN CONNECTION WITH TRANSACTION.  Full Article

Photo

British fraud office abandons Rolls-Royce, GSK investigations

LONDON The UK's Serious Fraud Office (SFO) has abandoned two of its largest and longest investigations, into alleged bribery at aero engine maker Rolls-Royce and drugs maker GlaxoSmithKline, in a move described by one lawyer as "extraordinary".